Folate homeostasis of cancer cells affects sensitivity to not only antifolates but also other non-folate drugs: Effect of MRP expression

Pteridines

Volumn 24, Issue 1, 2013, Pages 81-86

  Peters, Godefridus J ^b   Kathmann, Ietje ^b   Lemos, Clara ^a,b   Hooijberg, Jan Hendrik ^b,c   Losekoot, Nienke ^b   Jansen, Gerrit ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

ABCC1; Anthracyclines; Folate; Leucovorin; Methotrexate; MRP1; Multidrug resistance

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FOLIC ACID; FOLIC ACID ANTAGONIST; GLUTATHIONE; GLUTATHIONE REDUCTASE; HOMOCYSTEINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG SENSITIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMEOSTASIS; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

EID: 84882430778     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pterid-2013-0019     Document Type: Article

References (27)

1. Bertino JR. "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. Semin Oncol 1977;4(Suppl 2):203-16.
2. Zervos PH, Allen RH, Thornton DE, Thiem PA. Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Eur J Cancer 1997;33(Suppl):S18.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-44.
4. Hooijberg JH, Jansen G, Assaraf YG, Kathmann I, Pieters R, Laan AC, et al. Folate concentration dependent transport activity of the multidrug resistance protein 1 (ABCC1). Biochem Pharmacol 2004;67:1541-8.
5. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
6. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-Associated proteins. J Natl Cancer Inst 2000;92:1295-302.
7. Hooijberg JH, De Vries NA, Kaspers GJ, Pieters R, Jansen G, Peters GJ. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 2006;58:1-12.
8. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5.
9. Kool M, Van der Linden M, De Haas M, Scheffer GL, De Vree ML, Smith AJ, et al. MRP3, a new organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-8.
10. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of poly-glutamylation on MTX transport. Cancer Res 2001;61:7225-32.
11. Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 2000;92:1934-40.
12. Cronstein BN. Methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
13. Hooijberg JH, Peters GJ, Assaraf YG, Kathmann I, Priest DG, Bunni MA, et al. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem Pharmacol 2003;65:765-71.
14. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996;56:988-94.
15. Keepers YP, Pizao PE, Peters GJ, Van Ark-Otte J, Winograd B, Pinedo HM. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991;27:897-900.
16. Backus HH, Pinedo HM, Wouters D, Padron JM, Molders N, Van der Wilt CL, et al. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int J Cancer 2000;87:771-8.
17. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM. Antioxidants and cancer therapy: a systematic review. J Clin Oncol 2004;22:517-28.
18. Priest DG, Schmitz JC, Bunni MA, Stuart RK. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 1991;83:1806-12.
19. Porcelli L, Assaraf YG, Azzaritti A, Jansen G, Paradiso A, Peters GJ. The impact of folate status on the efficacy of colorectal cancer treatment. Curr Drug Metab 2011;12:975-84.
20. Choumenkovitch SF, Selhub J, Wilson PW, Rader JI, Rosenberg IH, Jacques PF. Folic acid intake from fortification in United States exceeds predictions. J Nutr 2002;132: 2792-8.
21. Peters GJ, Jansen G. Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition 2001;17: 737-8.
22. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998;273:30189-98.
23. Zhao R, Gao F, Liu L, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of the folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-65.
24. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the Mw 190,000 kD multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 1998;58:55130-6.
25. Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochem Biophys Acta 1999;1461:347-57.
26. Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol 1993;14:683-93.
27. Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I, et al. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem 2003;278:6680-6.